Goyal Amit Kumar, Garg Tarun, Rath Goutam, Gupta Umesh Datta, Gupta Pushpa
J Biomed Nanotechnol. 2016 Mar;12(3):450-63. doi: 10.1166/jbn.2016.2180.
The major goal of the current research was to develop and evaluate the therapeutic potential of anti-tubercular drugs (ATDs) loaded natural polysaccharide comprising of galacto mannan subunit in experimental tuberculosis (TB). Experimental formulations were prepared by ionotropic gelation technique followed by spray drying. Morphological analysis suggested that optimized nanoparticles were found to be discrete and spherical in nature with a particle size distribution range from 230 ± 4.5 nm to 310 ± 6.2 nm. The in-vitro drug release behavior indicated the biphasic pattern comprising of initial burst followed by a sustained release pattern. Guar gum coated chitosan nanoparticles (CGNPs) among the leading formulation exhibited the highest cell uptake potential confirmed by FACS analysis. Challenge study also supports the in-vivo bio-distribution illustrated by the significant reduction in CFU count in experimental TB in mice. Histopathology study demonstrated that none of the treated group shows any evidence of lung tissue abnormality. Hence, the study marked the fact that CGNPs could be a promising carrier for selective delivery of ATDs to alveolar macrophages for efficient management of TB with the interception of minimal side effects.
当前研究的主要目标是开发并评估负载抗结核药物（ATD）的、由半乳甘露聚糖亚基组成的天然多糖在实验性结核病（TB）中的治疗潜力。通过离子凝胶化技术制备实验制剂，随后进行喷雾干燥。形态学分析表明，优化后的纳米颗粒呈离散球形，粒径分布范围为230±4.5纳米至310±6.2纳米。体外药物释放行为呈现双相模式，包括初始突释和随后的缓释模式。在主要制剂中，瓜尔胶包衣的壳聚糖纳米颗粒（CGNP）表现出最高的细胞摄取潜力，这通过流式细胞术分析得到证实。攻毒研究也支持体内生物分布情况，表现为实验性小鼠结核病中菌落形成单位（CFU）计数显著减少。组织病理学研究表明，没有一个治疗组显示出肺组织异常的任何迹象。因此，该研究表明，CGNP可能是一种有前景的载体，可将ATD选择性递送至肺泡巨噬细胞，以有效管理结核病，同时将副作用降至最低。
